GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Financial Strength

ARDX (Ardelyx) Financial Strength : 5 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Financial Strength?

Ardelyx has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Ardelyx did not have earnings to cover the interest expense. Ardelyx's debt to revenue ratio for the quarter that ended in Mar. 2025 was 0.52. As of today, Ardelyx's Altman Z-Score is 0.66.


Competitive Comparison of Ardelyx's Financial Strength

For the Biotechnology subindustry, Ardelyx's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Financial Strength distribution charts can be found below:

* The bar in red indicates where Ardelyx's Financial Strength falls into.


;
;

Ardelyx Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Ardelyx's Interest Expense for the months ended in Mar. 2025 was $-6.3 Mil. Its Operating Income for the months ended in Mar. 2025 was $-36.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $153.8 Mil.

Ardelyx's Interest Coverage for the quarter that ended in Mar. 2025 is

Ardelyx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Ardelyx's Debt to Revenue Ratio for the quarter that ended in Mar. 2025 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2025 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.302 + 153.806) / 296.456
=0.52

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Ardelyx has a Z-score of 0.66, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.66 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ardelyx  (NAS:ARDX) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Ardelyx has the Financial Strength Rank of 5.


Ardelyx Financial Strength Related Terms

Thank you for viewing the detailed overview of Ardelyx's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Executives
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010